D. Parker

发表

Induced sputum inflammatory mediator concentrations in chronic cough.

I. Pavord, S. Birring, C. Brightling, 2004, American journal of respiratory and critical care medicine.

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.

I. Pavord, K. Rabe, C. Brightling, 2003, American journal of respiratory and critical care medicine.

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease

I. Pavord, S. Birring, B. Hargadon, 2005, Thorax.

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial

I. Pavord, B. Hargadon, C. Brightling, 2007, European Respiratory Journal.

Sputum eosinophilia in idiopathic pulmonary fibrosis

I. Pavord, S. Birring, B. Hargadon, 2005, Inflammation Research.

The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection.

J. Elborn, S. M. Cordon, D. Shale, 1993, Respiratory medicine.

Profiling of Sputum Inflammatory Mediators in Asthma and Chronic Obstructive Pulmonary Disease

B. Hargadon, C. Brightling, M. Bafadhel, 2011, Respiration.

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol.

I. Pavord, I. Naya, Jie Zhu, 2009, The Journal of allergy and clinical immunology.

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma

I. Pavord, A. Woodcock, D. Parker, 2007, Respiratory research.

Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor.

D. Shale, D. Parker, S. Westaby, 1993, The Journal of thoracic and cardiovascular surgery.

Evidence of a role of tumor necrosis factor alpha in refractory asthma.

I. Pavord, D. Shaw, B. Hargadon, 2006, The New England journal of medicine.

Granulocyte–macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD

C. Brightling, D. Parker, M. Sleeman, 2009, Thorax.

Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis.

I. Pavord, A. Morgan, C. Brightling, 2004, The Journal of allergy and clinical immunology.

The influence of age on induced sputum differential cell counts in normal subjects.

I. Pavord, S. Birring, C. Brightling, 2004, Chest.

A placebo controlled comparison of formoterol, montelukast or higher dose of inhaled corticosteroids in subjects with symptomatic asthma despite treatment with low dose inhaled corticosteroids

I. Pavord, B. Hargadon, C. Brightling, 2002 .

Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial

I. Pavord, S. Birring, Sérgio Matos, 2010, Thorax.

THORAXJNL142711 1..4

I. Pavord, S. Birring, Sérgio Matos, 2022 .

Effects of Exercise and Diet in Nonobese Asthma Patients-A Randomized Controlled Trial.

A. Astrup, C. Porsbjerg, V. Backer, 2017, The journal of allergy and clinical immunology. In practice.

Airway function and markers of airway inflammation in patients with treated hypothyroidism

S. Birring, B. Hargadon, I. Pavord, 2005, Thorax.

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial

I. Pavord, C. Brightling, A. Wardlaw, 2000, The Lancet.

Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids

I. Pavord, C. Brightling, A. Wardlaw, 2002, Thorax.

Induced sputum and bronchial mucosal expression of interleukin‐13 is not increased in chronic obstructive pulmonary disease

I. Pavord, C. Brightling, P. Bradding, 2008, Allergy.

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma

I. Pavord, A. Morgan, D. Shaw, 2007, Thorax.

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial

I. Pavord, B. Hargadon, C. Brightling, 2002, The Lancet.

Systemic inflammatory responses to cardiopulmonary bypass: a pilot study of the effects of pentoxifylline.

D. Shale, D. Parker, S. Westaby, 1993, Respiratory medicine.

SYSTEMIC RELEASE OF NEUTROPHIL ELASTASE AND TUMOUR NECROSIS FACTOR ALPHA FOLLOWING ABO INCOMPATIBLE BLOOD TRANSFUSION

D. Parker, R. Pillai, J. Butler, 1991, British journal of haematology.

Increased sputum and bronchial biopsy IL-13 expression in severe asthma.

I. Pavord, A. Morgan, C. Brightling, 2008, The Journal of allergy and clinical immunology.

The Diagnostic and Prognostic Accuracy of Five Markers of Serious Bacterial Infection in Malawian Children with Signs of Severe Infection

M. Molyneux, C. Hart, R. Heyderman, 2009, PloS one.

Effect of fluorocarbon liquid on surface tension properties of pulmonary surfactant.

D. Parker, J. Modell, F. Gollan, 1970, Chest.

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness

I. Pavord, I. Hall, B. Hargadon, 2006, European Respiratory Journal.

Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control.

I. Pavord, F. Hargreave, P. Corris, 2007, Respiratory medicine.

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.

I. Pavord, N. Thomson, Jie Zhu, 2006, American journal of respiratory and critical care medicine.

Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability.

I. Pavord, C. Brightling, M. Morgan, 2001, Respiratory medicine.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease

S. Birring, B. Hargadon, D. Parker, 2005 .